EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the first ...

Researchers at UC San Diego have discovered that the enzyme MICAL2 accelerates tumor growth in pancreatic cancer by ...

Pancreatic cancer kills 50,000 people each year, according to the National Cancer Institute, and there are few effective ...

Immuneering Corporation (IMRX) stock gains as company announces positive data for pancreatic cancer treatment and plans to ...

An enzyme called MICAL2 promotes tumor growth and metastasis in the most common form of pancreatic cancer, according to a new study.

(RTTNews) - Immuneering Corp. (IMRX), Tuesday announced positive data update from three arms of its ongoing Phase 2a trial of lead program IMM-1-104 for the treatment of patients with Pancreatic ...

Pancreatic cancer is one of the most lethal malignancies, with nearly 50,000 deaths annually in the United States, according ...

Shares of Immuneering Corporation (NASDAQ:IMRX) surged 55% following the release of encouraging data from its ongoing Phase 2a trial of IMM-1-104, a therapy for pancreatic cancer. The Cambridge-based ...

With limited treatment options available for patients with PDAC, the EMA Orphan Drug Designation and FDA Orphan Drug Designation granted to elraglusib for the same indication reflect elraglusib’s ...

Long before mRNA vaccines captured global attention during the COVID-19 pandemic, researchers were already exploring their ...